Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1042-1051

  Zuo, M ^a   Rashid, A ^a   Churi, C ^a   Vauthey, J N ^b   Chang, P ^a   Li, Y ^a   Hung, M C ^a   Li, D ^a   Javle, M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

BTC; combination therapy; Hedgehog inhibitor; mTOR inhibitor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NERVE GROWTH FACTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN KINASE B; RAPAMYCIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR NANOG; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; GLI1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; MTOR PROTEIN, HUMAN; NANOG PROTEIN, HUMAN; PYRIDINE DERIVATIVE; S6 KINASE; SONIC HEDGEHOG PROTEIN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

ARTICLE; BILIARY TRACT CANCER; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BILIARY TRACT NEOPLASMS; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANILIDES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; G1 PHASE; GENE EXPRESSION PROFILING; HEDGEHOG PROTEINS; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PYRIDINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925334894     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.625     Document Type: Article

References (32)

1. Acevedo-Gadea C, Santin AD, Higgins SA, Urva S, Ratner E, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Abu-Khalaf MM (2014) Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. Int J Gynecol Cancer 24(3): 528-533.
2. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, GillenMC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS (2012) Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142(4): 1021-1031 e1015.
3. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ (2012) Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 17(1): 72-79.
4. Buzzoni R, Pusceddu S, Bajetta E, De Braud F, Platania M, Iannacone C, Cantore M, Mambrini A, Bertolini A, Alabiso O, Ciarlo A, Turco C, Mazzaferro V (2014) Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. Ann Oncol 25(8): 1597-1603.
5. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
6. David JM, Rajasekaran AK (2012) Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res 72(12): 2917-2923.
7. Douville J, Beaulieu R, Balicki D (2009) ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 18(1): 17-25.
8. El Khatib M, Kalnytska A, Palagani V, Kossatz U, Manns MP, Malek NP, Wilkens L, Plentz RR (2013) Inhibition of hedgehog signaling attenuates carcinogenesis in vitro and increases necrosis of cholangiocellular carcinoma. Hepatology 57(3): 1035-1045.
9. Herberger B, Berger W, Puhalla H, Schmid K, Novak S, Brandstetter A, Pirker C, Gruenberger T, Filipits M (2009) Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells. Mol Cancer Ther 8(6): 1547-1556.
10. Herberger B, Puhalla H, Lehnert M, Wrba F, Novak S, Brandstetter A, Gruenberger B, Gruenberger T, Pirker R, Filipits M (2007) Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 13(16): 4795-4799.
11. Jenkins D (2009) Hedgehog signalling: emerging evidence for non-canonical pathways. Cel Signal 21(7): 1023-1034.
12. Kim YJ, Park SB, Park JY, Park SW, Chung JB, Song SY, Bang S (2012) The sonic hedgehog pathway as a treatment target for extrahepatic biliary tract cancer. Mol Med Rep 5(1): 12-16.
13. Lauth M, Toftgard R (2007) Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. Cell Cycle 6(20): 2458-2463.
14. Leal P, Garcia P, Sandoval A, Letelier P, Brebi P, Ili C, Alvarez H, Tapia O, Roa JC (2013) Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. Arch Pathol Lab Med 137(4): 552-557.
15. LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerivitz KL, Low JA, Von Hoff DD (2011) Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17(8): 2502-2511.
16. Mohamet L, Hawkins K, Ward CM (2011) Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. J Oncol 2011: 352616.
17. Moolthiya P, Tohtong R, Keeratichamroen S, Leelawat K (2014) Role of mTOR inhibitor in cholangiocarcinoma cell progression. Oncol Lett 7(3): 854-860.
18. Poomphakwaen K, Promthet S, Kamsa-Ard S, Vatanasapt P, Chaveepojnkamjorn W, Klaewkla J, Sujirarat D, Pichainarong N (2009) Risk factors for cholangiocarcinoma in Khon Kaen, Thailand: a nested case-control study. Asian Pac J Cancer Prev 10(2): 251-258.
19. Putzke AP, Ventura AP, Bailey AM, Akture C, Opoku-Ansah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, Corey E, Tewari M, Morrissey C, Vessella RL, Knudsen BS (2011) Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol 179(1): 400-410.
20. Razumilava N, Gradilone SA, Smoot RL, Mertens JC, Bronk SF, Sirica AE, Gores GJ (2014) Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma. J Hepatol 60(3): 599-605.
21. Riedlinger D, Bahra M, Boas-Knoop S, Lippert S, Bradtmoller M, Guse K, Seehofer D, Bova R, Sauer IM, Neuhaus P, Koch A, Kamphues C (2014) Hedgehog pathway as a potential treatment target in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci 21(8): 607-615.
22. Rodova M, Fu J, Watkins DN, Srivastava RK, Shankar S (2012) Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer stem cell self-renewal. PLoS One 7(9): e46083.
23. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144(4): 829-840.
24. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1): 9-29.
25. Simbolo M, Fassan M, Ruzzenente A,Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, de Braud F, Scarpa A (2014) Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 5(9): 2839-2852.
26. Tang L, Tan YX, Jiang BG, Pan YF, Li SX, Yang GZ, Wang M, Wang Q, Zhang J, Zhou WP, Dong LW, Wang HY (2013) The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma. Clin Cancer Res 19(8): 2014-2024.
27. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters Jr. JC, de Sauvage FJ, Low JA (2009) Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361(12): 1164-1172.
28. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC, Kipp BR (2013) Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 44(7): 1216-1222.
29. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC (2012) The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21(3): 374-387.
30. Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE (2011) Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and liganddependent Hedgehog pathway activation. Clin Cancer Res 17(14): 4682-4692.
31. Wu Q, Kiguchi K, Kawamoto T, Ajiki T, Traag J, Carbajal S, Ruffino L, Thames H, Wistuba I, Thomas M, Vasquez KM, DiGiovanni J (2007) Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 67(8): 3794-3800.
32. Zong H, Yin B, Zhou H, Cai D, Ma B, Xiang Y (2014) Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition. Mol Biol Rep 41(7): 4507-4512.